Robert Cameron, MD, FACS: Treatment of Mesothelioma as a Sarcoma

Robert Cameron, MD, FACS, on Treatment of Mesothelioma as a Sarcoma: Implications for Surgcal Timing and Techniques at 3rd International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma on May 18, 2013.

Dr. Cameron the course organizer and the Director of the UCLA Comprehensive Mesothelioma Program, has had over 19 years of experience with treating patients with MPM and, in particular, lung-sparing therapies, including pleurectomy and decortication surgical procedures and a number of complementary adjuvant therapies with the goal of treating this deadly disease like a chronic illness, similar to hypertension and diabetes.

Malignant pleural mesothelioma (MPM) is an unusual cancer because it grows throughout the chest cavity as a diffuse process rather than a typical solid nodule or mass. Because of this unique characteristic, it has very specific treatment issues.

MPM also is an unusual tumor with less than 3000 new cases annually, and therefore, most physicians, even pulmonologists and medical oncologists, may only see these patients infrequently. Despite this, it is critical that all physicians involved in the care of MPM patients be familiar with the important issues in this disease and possess a thorough understanding regarding the tumor itself, its evaluation process, staging, treatment and the role of multidisciplinary management of these patients. This includes the role and extent of surgery as well as radiation, chemotherapy and newer targeted therapies.

For more info on the 3rd International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma:

Researchers at the 3rd International Symposium on Lung-Sparing Therapies for Mesothelioma Present Promising Treatments for Extending Survival and Improving Quality of Life for Victims